Original article
Pancreas, biliary tract, and liver: Editorial
Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival

https://doi.org/10.1016/j.cgh.2015.07.018Get rights and content

References (27)

  • R.C. Dickson et al.

    Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation

    Transplantation

    (1996)
  • K. Radecke et al.

    Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis

    Liver Int

    (2005)
  • A.A. Prachalias et al.

    Liver transplantation in adults coinfected with HIV

    Transplantation

    (2001)
  • Cited by (3)

    • How I treat hepatitis C virus infection in patients with hematologic malignancies

      2016, Blood
      Citation Excerpt :

      In both the liver transplant and HCT settings, use of mycophenolate mofetil has been linked to development of fibrosing cholestatic hepatitis C; thus, this drug should probably not be used in HCV-infected patients.29,81 In the HCT setting, DAAs against HCV would likely reduce the burden of intracellular virus29 and reduce the mortality rate of fibrosing cholestatic hepatitis C, as has been observed with successful DAA therapy of fibrosing cholestatic hepatitis C in the liver transplant setting.82-84 In a parallel situation, the frequency of fibrosing cholestatic hepatitis B in HCT recipients has plummeted since the introduction of pre-emptive use of lamivudine or entecavir.85

    Conflicts of interest This author discloses the following: Norah Terrault has received research support from Gilead, Genetech/Roche, Vertex, Novartis, Eisai, and AbbVie, and has served as a consultant for Bristol-Myers Squibb. None of these companies had any role in this study. The remaining author discloses no conflicts.

    Funding Supported by scholarships from Hepatology and Gastroenterology Services, Centre Hospitalier de l'Université de Montréal and the Fondation du Centre Hospitalier de l'Université de Montréal (J.M.G.), and by the University of California San Francisco Liver Center (National Institutes of Health P30 DK 026743 to N.A.T.).

    View full text